Women whose cells harbor harmful mutations in the BRCA genes are likely to view preventive mastectomy as the best way to reduce their risk and fears of developing breast cancer, despite other, less drastic options available.
That is the conclusion of a new study published in the April 1, 2009 issue of CANCER , a peer-reviewed journal of the American Cancer Society. The study's findings could help physicians and other clinicians as they discuss test results with women who undergo BRCA gene testing.
Women at high risk for developing breast cancer have several options to help safeguard against the disease. Risk management for women with a known deleterious mutation in either the BRCA1 or BRCA2 genes has included frequent screening with mammogram, breast MRI, and clinical breast exams, tamoxifen therapy, and risk reduction surgeries including prophylactic mastectomy. To get a sense of women's opinions regarding those options, particularly frequent screening versus prophylactic mastectomy, researchers led by Jennifer K. Litton, M.D., of The University of Texas M. D. Anderson Cancer Center in Houston surveyed women at their institution who underwent BRCA1 and BRCA2 genetic testing. When mutated, BRCA1 and BRCA2 are known to elevate the risk for the development of breast cancer.
Of the 312 women surveyed, 86 had tested positive for a BRCA mutation. Seventy percent of the women who tested positive for a BRCA mutation felt that preventive mastectomy was the most effective way to reduce their risk of developing breast cancer, compared with 40 percent of women who tested negative for a BRCA mutation. Similarly, 64.7 percent of BRCA positive women felt that preventive mastectomy was the only way to reduce their worry, compared with 34.4 percent of BRCA negative women.